

Pilot Study of a Moderate Dose Multivitamin/Mineral Supplement for Children with Autistic Spectrum Disorder

JAMES B. ADAMS, Ph.D., and CHARLES HOLLOWAY, B.S.

ABSTRACT

Objective: Determine the effect of a moderate dose multivitamin/mineral supplement on children with autistic spectrum disorder.

Design: Randomized, double-blind, placebo-controlled 3-month study.

Subjects: Twenty (20) children with autistic spectrum disorder, ages 3–8 years.

Results: A Global Impressions parental questionnaire found that the supplement group reported statistically significant improvements in sleep and gastrointestinal problems compared to the placebo group. An evaluation of vitamin B₆ levels prior to the study found that the autistic children had substantially elevated levels of B₆ compared to a control group of typical children (75% higher, $p < 0.0000001$). Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.

Discussion: The finding of high vitamin B₆ levels is consistent with recent reports of low levels of pyridoxal-5-phosphate and low activity of pyridoxal kinase (i.e., pyridoxal is only poorly converted to pyridoxal-5-phosphate, the enzymatically active form). This may explain the functional need for high-dose vitamin B₆ supplementation in many children and adults with autism.

INTRODUCTION

Nutritional deficiencies are widespread in the United States. For example, ~30% of the general population has a marginal vitamin C status, and ~15% of Americans are vitamin C deficient (Hampl et al., 2000; Johnston and Thompson, 1998). Low levels of other vitamins and minerals, including calcium, iron, folic acid, magnesium, and chromium continue to be a significant problem in the United States and other countries (Anderson, 1992; Murray, 1996).

Based on these findings, it is not surprising that a number of studies and reviews have demonstrated the benefits of targeted multivitamin/mineral nutritional supplementation in the improvement of IQ, scholastic test scores, early neurological development, and behavioral, cognitive, and academic gains in children with learning disabilities (Carlton et al., 2000; Fernstrom, 2000; Shoenthaler, 2000).

Many studies find or suggest that people with autism have functionally low level of essential vitamins and minerals.

Measurements of vitamin/mineral levels

Audhya and colleagues recently reported measurements of vitamin and mineral levels in the blood of over 150 children with autism compared to 50–100 controls of the same age (Adams et al., 2003). They found that the children with autism on average had much lower levels of most vitamins (vitamins A, C, D, and E, and all B vitamins except choline) and some minerals (zinc, magnesium, selenium).

High copper:zinc ratio

Analysis of data from the Pfeiffer laboratory found that over 99% of 500 children with autism had an elevated serum copper:plasma zinc ratio, higher than that for any other

group they had tested (Walsh, 2001). It has been hypothesized that this imbalance is related to a metallothionein defect, and suggests that people with autism should avoid copper and take extra zinc.

B12 deficiency

A functional B12 deficiency has been suggested by a study that found elevated urinary methylmalonic acid in autistics (Wakefield et al., 1998).

Calcium deficiency

Landgrebe found that 22% of autistic children measured low 24-hour urinary calcium excretion (Landgrebe and Landgrebe, 1976).

Sulfate deficiency

Two studies have found that children with autism often have abnormal sulfate metabolism, leading to excess urinary excretion of sulfate and very low plasma levels of sulfate (Alberti et al., 1999; O'Reilly and Waring, 1993).

Vitamin A

Megson (2000) has hypothesized that children with autism may have a Vitamin A deficiency.

Reasons for low levels of nutrients in children with autism

Chronic diarrhea/constipation. Malabsorption problems in autism were first documented over 30 years ago (Goodwin et al., 1971). A recent study by the Southwest Autism Research Center of over 400 people with autism has found that 48% reported chronic diarrhea or chronic constipation (Schneider and Melmed, 2000).

Gastrointestinal inflammation. There is substantial evidence of chronic gastrointestinal (GI) inflammation and structural compromise in the digestive tract in many people with autism, especially in the terminal ileum, which is the major site for nutrient absorption (Horvath et al., 1999; Wakefield et al., 2000). This intestinal inflammation likely reduces nutrient absorption.

Dietary restrictions. One of the classic symptoms of autism is restricted interests and behaviors and, in our clinical experience, this often includes choices of food. Restricted, self-limited diets are more likely to be deficient in one or more essential nutrients.

Benefits of nutritional supplements

Rimland (2001) conducted an open survey of thousands of parents of children with autism to determine which treat-

ments they found to be helpful or harmful. The study found that parents reported supplements of calcium, vitamin C, folic acid, and vitamin B6 with magnesium, zinc, niacin, niacinamide, and dimethylglycine resulted in improvement in 41–58% of cases versus 1–8% responding that the supplements worsened symptoms.

Benefits of B6/magnesium. Eighteen (18) studies on the efficacy and safety of very high doses of vitamin B₆ with magnesium, including 11 double-blind placebo-controlled studies, have been conducted over the past 35 years and the results have repeatedly shown this combination to be effective in reducing many of the deficits and symptoms of autism (Barthelemey et al., 1981, 1983; Bonish, 1968; Coleman et al., 1979; Ellman, 1981; Garner et al., 1986; Gaultier et al., 1981; Jonas et al., 1984; LeLord et al., 1981, 1988; Martineau et al., 1982, 1985, 1986; Rimland, 1973, 1974, 1987; Rimland et al., 1978; Rossl et al., 1990).

Vitamin C. Vitamin C has also been shown in a clinical trial to facilitate a reduction in symptom severity in children with autism (Dolske et al., 1993).

MATERIALS AND METHODS

The objectives of this study were to determine the levels of vitamin B₆, vitamin C, and alpha lipoic acid in children with autistic spectrum disorder; and to determine if a moderate dose multivitamin/mineral supplement is effective in partially reducing some of the symptoms of autism.

The study methodology was approved by the Human Subjects Institutional Review Board at Arizona State University. The parents of all participants signed informed consent forms.

The study was advertised by a mass mailing sent to approximately 1000 families of people with autism in the state of Arizona, using the combined mailing lists of the Greater Phoenix Chapter of the Autism Society of America and the Southwest Autism Research Center.

The selection criteria for the study included age 3–8 years; diagnosis of an autism spectrum disorder (autism, pervasive developmental disorder—not otherwise specified [PDD/NOS], or Asperger's syndrome) by a psychiatrist or developmental pediatrician; no changes in any treatment therapies during the previous 2 months, including psychiatric medications, nutritional supplements, diet, or behavioral therapy program, as well as an agreement to make no such changes during the 3 months of the study; and no prior use of a multivitamin/mineral supplement other than a standard children's multivitamin/mineral. Any standard supplements were discontinued prior to the study.

Twenty-five (25) applicants who applied met the criteria, and they were enrolled in the study. The children were matched in pairs by age and sex, and then a random selec-

tion was made to determine which child received the supplement and which the placebo.

The study began with an initial physical evaluation conducted by a physician to determine that the children were in reasonable physical health. Then a blood and first morning urine sample were collected. The children took the supplements for 3 months, and were then re-examined by the physician, and additional blood specimens were collected. The parents, physicians, and children were blinded regarding who received the supplement and who received the placebo.

The levels of vitamin B₆ in plasma were measured at the beginning and end of the study by Vitamin Diagnostics Laboratory. The measurements were carried out using the ciliate protozoan *Tetrahymena pyriformis* (Baker et al., 1966). The standards were prepared by mixing pyridoxal hydrochloride, pyridoxamine dihydrochloride, and pyridoxal-5-phosphate in equal ratio. The assay measures the total amount of vitamin B₆, including pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated forms. This is an older method, still used by commercial labs due to its reliability.

At the beginning of the study, prior to supplementation, the level of alpha lipoic acid was also measured by Vitamin Diagnostics. The measurements were carried out using a protozoan assay with *T. pyriformis* (Baker et al., 1998).

Vitamin C was measured on the last day of the study (due to logistical problems it could not be measured at the beginning). Blood was collected in EDTA-treated vacutainers, immediately processed, and an aliquot of plasma was mixed with an equal volume of 10% TCA. The supernatant was frozen (-45°C) for later vitamin C analysis using the colorimetric 2,4-dinitrophenylhydrazine method (Omaye et al., 1979).

Statistical analysis was conducted with a simple *t*-test comparison, assuming a normal distribution and setting a level of $p = 0.05$ for statistical significance.

Choice of supplement

We wanted to investigate a commercial supplement that was in use by children with autism. We chose Spectrum Support (BrainChild Nutritionals, Santa Cruz, CA) because it contains a broad range of most vitamins and minerals, does not contain copper, and has moderate amounts of vitamin B₆ (Table 1). Also, the liquid formulation and taste helped with compliance (only one child had a significant compliance problem).

Dosage

The dosage was gradually increased during the study. The dosage began with the Spectrum Support II (SSII) formulation, starting at $\frac{1}{8}$ of the dose, and increased linearly over 24 days to the maximum dose of SSII, which was held constant until day 34. During days 35–50, there was a gradual transition to Spectrum Support III (SSIII), which was con-

tinued until day 90 at the same volume (SSIII is similar to SSII, with the major difference being a slightly higher concentration of nutrients). The full dosage was 1 mL/5 pounds bodyweight, t.i.d. with food, for a total daily intake of 3 mL/5 pounds bodyweight.

Both SSII and SSIII are liquid suspensions in a Kosher vegetable glycerine base, flavored with lemon, lime, and grapefruit essential oils and preserved with grapefruit seed extract, pau d'arco, and potassium sorbate. Trace amounts of burdock root, chinese astragalus root, chinese licorice root, ginkgo, gotu kola, siberian ginseng, and slippery elm are added.

Placebo

The placebo was the same Kosher vegetable glycerine base, with hibiscus added to match the coloring of the supplement. The coloring faded over time, so it was not an extract match, but the consistency remained very similar to the supplement. Because the parents and children did not know what the true SSII or SSIII looked like, this did not appear to be a significant issue, and at the end of the study the parents were still unsure whether or not they had received the supplement.

Elimination of participants

Five (5) children who began the study were not included in the final evaluation. In the placebo group, 3 children withdrew. One child, with a history of diarrhea, developed diarrhea 2 weeks into the study; the parent stopped the "supplement," but diarrhea continued for another week. The second child began risperidol therapy 2 weeks into the study, and was removed from the study. In the third case, the child dropped out prior to beginning supplement, to enter another study, on secretin. In the supplement group, 1 child withdrew after two months, when the family went on a one-month vacation and stopped giving the supplement, and another child did not take the supplement consistently, due to several factors including unwillingness, travel, ear surgery, and flu.

Final participant list

The 9 participants in the placebo group who completed the study were 8 boys and 1 girl; mean age 5 years 5 months; 6 with autism and 3 with PDD/NOS. The 11 participants in the supplement group who completed the study were 10 boys and 1 girl; mean age 5 years 2 months; 9 with autism and 2 with PDD/NOS.

Adverse side-effects

There were no adverse events reported in children who followed the dosage instructions. However, 2 of the children (twins) took the supplement with meals for breakfast and

TABLE 1. INGREDIENTS OF SPECTRUM SUPPORT II AND III (PER 30 mL)

	<i>SSII</i>	<i>SSIII</i>
Vitamins		
Pro-vitamin A mixed carotenoids from Dunaliella Salina		
Alpha and beta-carotene and cryptoxanthin	7500 IU	10,500 IU
Lutien and zeaxanthin	60 IU	84 IU
B ₁ (thiamin hydrochloride)	20 mg	30 mg
B ₂ (riboflavin-5-phosphate-coenzyme B ₂)	25 mg	25 mg
B ₃ (inositol hexaniacinate)	25 mg	35 mg
B ₅ (calcium pantothenate)	45 mg	25 mg
B ₆ (pyridoxyl-5-phosphate-coenzyme B ₆)	30 mg	30 mg
B ₁₂ (cyanocobalamin)	1200 mcg	1600 mcg
Folic acid	800 mcg	800 mcg
Biotin	100 mcg	150 mcg
Choline (citrate)	50 mg	60 mg
Inositol (monophosphate)	50 mg	60 mg
Vitamin C ascorbates (magnesium, potassium, and zinc ascorbates)	650 mg	800 mg
Mixed bioflavonoids	200 mg	400 mg
Vitamin D-3 (cholecalciferol)	150 IU	150 IU
Vitamin E	175 IU	250 IU
Minerals ^a		
Calcium (Kreb's chelates)	175 mg	200 mg
Calcium D-glucarate		75 mg
Chromium (picolinate)	75 mcg	100 mcg
Magnesium (Kreb's chelates and magnesium ascorbate)	175 mg	200 mg
Manganese (succinate)	3 mg	3 mg
Molybdenum (Kreb's chelate)	0	75 mcg
Potassium (alpha ketoglutarate and potassium ascorbate)	75 mg	75 mg
Selenium (selenomethionine)	70 mcg	85 mcg
Silicon (sodium metasilicate)		3 mg
Sulfur (methylsulfonylmethane, or MSM)	175 mg	300 mg
Zinc (picolinate, Kreb's chelates, and zinc ascorbate)	15 mg	20 mg
Other ingredients		
Betaine (trimethylglycine)	300 mg	400 mg
DMAE (bitartrate)	100 mg	100 mg
N-acetyl cysteine	25 mg	50 mg
Alpha lipoic acid (thiocitic acid)	0	25 mg

^aThe minerals are reported by the mass of the total molecule, not by the mass of the active mineral. Thus the dose of the active mineral is actually lower.

lunch, but at night they took it at 9 PM on an empty stomach (4 hours after dinner). There were no problems until week 9 of the study, when they began to have nausea and vomiting in the late evening after taking the supplement (no

problems during the day). This lasted for several weeks. When the investigators learned of the problem, they corrected the dosage time. The children completed the study, and their results are included in Table 2, but their outcome

TABLE 2. IMPRESSIONS BY MOTHERS OF 20 CHILDREN AT THE END OF THE STUDY (9 ON PLACEBO, 11 ON SUPPLEMENT), BASED ON CHANGES THEY OBSERVED, RANKED ON A 7-POINT SCALE^a

Category	Placebo score	Supplement score	Difference	P-value
Sleep	3.9	5.0	+1.1	0.03
Gastrointestinal symptoms	3.9	4.9	+1.0	0.03
Receptive language	4.9	5.5	+0.6	NS
General behavior	4.3	4.8	+0.5	NS
Eye contact	4.9	5.3	+0.4	NS
Expressive language	5.6	5.5	-0.1	NS
Sociability	5.1	5.0	-0.1	NS
Overall	5.1	5.1	+0.0	NS

^a1 = much worse; 2 = worse; 3 = slightly better; 4 = same; 5 = slightly better; 6 = better; 7 = much better
NS, nonsignificant

TABLE 3. VITAMIN C LEVELS AT END OF STUDY (MG/100 mL)

	<i>Placebo group</i> (n = 7)	<i>Supplement group</i> (n = 8)	<i>Typical children</i> (ages 3–5)	<i>Typical children</i> (ages 6–11)
Vitamin C	1.0 ± 0.17	1.33 ± 0.28	1.5 ^a	1.4 ^a

^aNational Center for Health Statistics (1982)

was understandably worse than for the other children, which somewhat reduced the overall significance of the results.

RESULTS AND DISCUSSION

Global impressions

On the last day of the study, the mothers of the children filled out a simple Global Impressions survey, to evaluate changes during the study. The forms were filled out privately by the mothers, with no input from the investigators. As can be seen in Table 2, the mothers reported some improvement for the children on the placebo (presumably due to a placebo effect), but there was generally more improvement for the children on the supplement than for those on the placebo. The improvements in sleep and GI symptoms were statistically significant (based on a simple *t*-test, assuming a normal distribution), with *p* < 0.05.

If the data are analyzed without including the two twins who mistakenly took the supplements on an empty stomach and suffered from vomiting/nausea, the mean improvements in GI and sleep symptoms are slightly higher (average 5.2 and 5.2) and more statistically significant (*p* = 0.005 and *p* = 0.01, respectively).

Vitamin C

According to a *t*-test, there was a statistically significant difference (*p* < 0.05) between the placebo and supplement group, which is to be expected as the supplement group received a high dose of vitamin C. The children in our study had a mean age of 5.5 years. The average vitamin C level for that age group is ~1.45 mg/100 mL (National Center for Health Statistics, 1982). The placebo group had a low level of vitamin C, 1.0 mg/100 mL, but even the supple-

mented group receiving a high dose of vitamin C still had a below average level of vitamin C of 1.33 mg/mL (Table 3). It is important to point out that a level of 0.5 mg/mL is considered a marginal deficiency, and a level of 0.2 mg/mL is considered a clinical deficiency. So, although the children with autism were not clinically deficient, they generally had low levels of vitamin C, and high-dose supplementation appeared to only partially help. Our results are consistent with a previous study (Dolske et al., 1993), which found that high-dose vitamin C supplementation led to clinical improvements in children with autism.

Vitamin B₆

The results are shown in Table 4. Prior to the start of supplementation, the children in the placebo group and the supplement group had similar vitamin B₆ levels (54 and 56 μg/mL, respectively). Those levels are well above the Vitamin Diagnostic laboratory's reference range of 22–47 for typical children ages 3–16; their reference range is defined as the lowest and highest values of the typical children. We also sent a set of plasma samples from typical children not taking vitamin supplements (age 6–9 years, *n* = 11) to the laboratory in a blinded fashion, and found that their average level was 32 μg/mL, consistent with the reference range. The difference between the total autism group and the typical children was highly statistically significant (*p* = 0.00000006). It is important to note that this measurement assesses total vitamin B₆, including pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated forms: pyridoxine-5-phosphate (PNP), pyridoxal-5-phosphate (PLP), and pyridoxamine-5-phosphate (PMP).

A previous study by Adams et al. (2003) found low levels of PLP in children with autism versus controls. PLP is a co-factor for many enzymatic reactions in the body, and is the active form of vitamin B₆. A study by Audhya (2002)

TABLE 4. ABNORMALLY HIGH LEVELS OF VITAMIN B6 (MG/ML) AT THE BEGINNING OF THE STUDY AND AT THE END OF THE STUDY IN CHILDREN WITH AUTISM

<i>Placebo group beginning</i> (n = 8)	<i>Placebo group end</i> (n = 7)	<i>Supplement group beginning</i> (n = 11)	<i>Supplement group end</i> (n = 10)	<i>All children beginning study</i> ^a (n = 24)	<i>Typical children</i> (ages 6–9) (n = 11)	<i>P-value</i> (All beginning children vs. typical children)	<i>Reference range</i> (ages 3–16) (n = 11)
54	65	56	92	55.5	32	0.00000006	22–47

^aPlacebo, supplement, and drop-outs.

found a very low activity of pyridoxal kinase (high K_m), the enzyme which converts pyridoxal and pyridoxamine into their active forms, PLP and PMP. Thus, a very slow conversion of pyridoxal and pyridoxamine would lead to elevated pyridoxal and pyridoxamine levels and low PLP and PMP levels, which is consistent with this study and the one by Audhya. This would explain why many studies of vitamin B6 have demonstrated a functional need for high doses of vitamin B6 (so that a sufficient amount is converted into the active forms prior to being excreted). Note that consumption of PLP is not necessarily any better than pyridoxal or pyridoxamine, as the phosphate group is likely removed during digestion.

Alpha lipoic acid

Alpha lipoic acid is currently being used in some heavy-metal detoxification treatments for autism, and we investigated whether its level was lower in the children with autism. The mean level was $3.7 \pm 0.6 \mu\text{g/mL}$. The reference group (typical adults, no data for children) has a range of 2.3–5.0 $\mu\text{g/mL}$. Thus, assuming that the extended time in frozen storage (12 months) did not significantly lower the value, it seems that the alpha lipoic acid levels are not abnormal, but a control group of children rather than adults is needed to properly interpret these results.

Limitations of this study

This pilot study had several limitations. First, the number of participants was small. Although some results were statistically significant according to a simple *t*-test, a larger study is needed to increase the statistical power.

Second, the behavioral assessment was limited to a very simple parental assessment, based on their observations over 3 months. More rigorous assessment tools are needed, including evaluations by professionals.

Third, the vitamin C measurements would be more valid if pretesting had been done in addition to the post-assessment. Also, the use of controls for vitamin C levels, rather than relying on national norms, would also increase the validity.

CONCLUSION

Based on a simple parental assessment, it appears that a 3-month treatment with a moderate-dose vitamin/mineral supplement (Spectrum Support) did result in a statistically significant improvement in sleep and GI problems in this group. However, a larger study is needed to increase the statistical power to determine if those results are generally valid.

Vitamin C levels were below average in children with autism not receiving the supplement, whereas those taking the supplement had near-normal levels.

Vitamin B₆ is significantly elevated in children with autism, probably due to defective pyridoxal kinase, implying a functional need for more. This may explain why very

high doses of vitamin B6 have been shown in numerous studies to benefit children with autism. A future study could measure pyridoxal, pyridoxamine, PMP, and PLP simultaneously to validate this interpretation.

Alpha lipoic acid levels were found to be similar to those found in typical adults, but data for children are needed to fully interpret these results.

ACKNOWLEDGMENTS

Most importantly, we thank the children with autism and their families for participating in this study. We thank Dr. Cindy Schneider, Raun Melmed, Carol Johnston, Richard Fabes, Lisa Dinella, Vitamin Diagnostics, and Tapan Audhya for their assistance. We thank Arizona State University, the Autism Society of America Foundation, the Greater Phoenix Chapter of the Autism Society of America, Families for Early Autism Treatment (FEAT)—Tucson, and the Southwest Autism Research Center (SARC) for their support. We thank BrainChild Nutritionals for supplying Spectrum Support at cost. The authors do not have any financial ties to BrainChild Nutritionals.

REFERENCES

- Adams JB, Audhya T, Vogelaar E. Nutritional Abnormalities in Autism and the Effect of Nutritional Supplementation. 2003 conference proceedings of the National Autism Society of America, Pittsburgh, PA, July 16–20, 2003.
- Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in “low-functioning” autistic children: a pilot study. *Biol Psychiatry* 1999;46:420–424.
- Anderson R. Chromium, glucose tolerance, and diabetes. *Biol Trace Elem Res* 1992;32:19–24.
- Baker H, Deangelis B, Baker ER, Hutner SH. A practical assay of lipoate in biological fluids and liver in health and disease. *Free Radical Biol Med* 1998;25:473–479.
- Baker H, Frank O, Ning M, Gellene R, Hutner S, Leevy C. A protozoological method for detecting clinical vitamin B₆ deficiency. *Am J Clin Nutr* 1966;18:123–133.
- Barthelmey C, Garreau B, Leddet I, Emout D, Muh J, LeLord G, Callaway E. Values of behavior scales and urinary homovanillic acid determinations in monitoring the combined treatment with vitamin B₆ and magnesium of children displaying autistic behavior [in French]. *Neuropsychiatrie de l'Enfance* 1983;31:289–301.
- Barthelmey C, Garreau B, Leddet I, Emout D, Muh J, LeLord G. Behavioral and biological effect of oral magnesium, vitamin B₆, and combined magnesium-B6 administration in autistic children. *Magnesium Bull* 1981;3:150–153.
- Bonish VE. Experiences with vitamin B₆ with brain-damaged children with autistic syndrome [in German]. *Proxis der Kinderpsychologie* 1968;8:308–310.
- Carlton R, Ente G, Blum L, Heyman N, Davis W, Ambeosino S. Rational dosages of nutrients have a prolonged effect on learning disabilities. *Altern Therap* 2000;6:85–91.
- Coleman M, Steinberg G, Tippell J, Bhagavan NH, Coursin DB, Gross M, Lewis C, DeVous L. A preliminary study of the ef-

- fect of pyridoxine administration in a subgroup of hyperkinetic children: A double blind crossover comparison with methylphenaldate. *Biol Psychiatr* 1979;4:741-751.
- Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. *Prog Neuropsychopharmacol Biol Psychiatry* 1993;17:765-774.
- Ellman G. Pyridoxine effectiveness on autistic patients at Sonoma State Hospital. Paper presented at Research Conference on Autism, San Diego, CA, November 1, 1981.
- Fernstrom JD. Can nutrient supplements modify brain function? *Am J Clin Nutr* 2000;71:1669S-1673S.
- Garner C, Conroy E, Barthelemy C, Leddet I, Carreau B, Muh JP, LeLord G. Dopamin-beta hydroxalase (DBH) and homovanillic acid (HVA) in autistic children. *J Autism Devel Disord* 1986;16:23-29.
- Gaulterir CT, Von Bourgonndien ME, Hartz C, Schopler E, Marcus L. Pilot study of pyridoxine treatment in autistic children. Paper presented at American Psychiatric Association meeting, New Orleans, LA, May 1981.
- Goodwin MS, Cowen MA, Goodwin TC. Malabsorption and cerebral dysfunction: a multivariate and comparative study of autistic children. *J Autism Child Schizophr* 1971;1:48-62.
- Hampel JS, Johnston CS, Taylor CA, N Hanes III. Data indicate that American subgroups have a high risk of vitamin C deficiency. *J Am Dietetics Assoc* 2000;100:A59.
- Horvath K, Papadimitriou JC, Rabsztyl A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. *J Pediatr* 1999;135:559-563.
- Johnston CS, Thompson LL. Vitamin C status of an outpatient population. *J Am Coll Nutr* 1998;17:366.
- Jonas C, Etienne T, Barthelemy C, Jouve J, Mariotte N. Clinical and biochemical value of magnesium + vitamin B₆ combination in the treatment of residual autism in adults [in French]. *Therapie* 1984;39:661-669.
- Landgrene MA, AR Landgrebe AR. Celiac autism: calcium studies and their relationship to celiac disease in autistic patients. In: Coleman M, ed. *The Autistic Syndromes*. New York: Elsevier, 1976:197-205.
- LeLord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E. Effects of pyridoxine and magnesium on autistic symptoms: initial observations. *J Autism Devel Disord* 1981;11:219-230.
- LeLord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E. Clinical and biological effects of vitamin B₆ + magnesium in autistic subjects. In: Leklem J and Reynolds R, eds. *Vitamin B6 Responsive Disorders in Humans*. New York: Alan R. Liss, 1988.
- Martineau J, Barthelemy C, Garreau B, LeLord G. Vitamin B₆, magnesium and combined B₆-Mg: therapeutic effects in childhood autism. *Biol Psychiatry* 1985;20:467-468.
- Martineau J, Barthelemy C, LeLord G. Long-term effects of combined vitamin B₆-magnesium administration in an autistic child. *Biol Psychiatry* 1986;21:511-518.
- Martineau J, Garreau B, Barthelemy C, Alelord O. Comparative effects of oral B₆, B₆-Mg, and Mg administration on evoked potentials conditioning in autistic children. In: Rothenberger A, ed. *Proceedings: Symposium on Event-Related Potentials in Children*, Essen, June 1982. Amsterdam: Elsevier Biomedical Press, 1982:411-416.
- Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? *Med Hyp* 2000;54:979-983.
- National Center for Health Statistics. *Hematological and Nutritional Biochemistry Reference Data for Persons 6 months-74 Years of Age: United States, 1976-1980*. Series 11, no. 232, 1982.
- National Research Council. *National Research Council Diet and Health: Implications for Reducing Chronic Disease Risk*. Washington, DC, 1989.
- O'Reilly BA, Waring R. Enzyme and sulfur oxidation deficiencies in autistic children with known food/chemical intolerances. *J Orthomolecular Med* 1993;4:198-200.
- Omaye WT, Turnbull JD, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cells, tissues, and fluids. *Meth Enzymol* 1979;62:3-11.
- Rimland B, Callaway E, Dreyfus P. The effects of high doses of vitamin B6 on autistic children: A double-blind crossover study. *Am J Psychiatry* 1978;135:472-475.
- Rimland B. An orthomolecular study of psychotic children. *Orthomolec Psychiatry* 1974;3:371-377.
- Rimland B. High dosage levels of certain vitamins in the treatment of children with severe mental disorders. In: Hawkins D, Pauling L, eds. *Orthomolecular Psychiatry*. New York: W.H. Freeman, 1973:513-538.
- Rimland B. Megavitamin B6 and magnesium in the treatment of autistic children and adolescents. In: Schopler E, Mesibov GB, eds. *Neurobiological Issues in Autism*. New York; Plenum, 1987:389-405.
- Rimland B. *Parent Ratings of Behavioral Results of Nutrients [ARI Publication 34]* San Diego. Autism Research Institute, 2001.
- Rossi P, Visconti P, Bergossi A, Balestra V. Effects of vitamin B₆ and magnesium therapy in autism. Conference on the Neurobiology of Infantile Autism, Tokyo, Japan, November 10-11, 1990.
- Schneider C, Melmed R. Beyond the Diagnosis. Autism/Aspberger's Conference, Tempe, AZ, January 9-10, 2004.
- Shoenthaler S. The effect of vitamin-mineral supplementation on the intelligence of American schoolchildren: a randomized, double-blind, placebo-controlled trial. *J Altern Complimentary Med* 2000;6:19-29.
- Wakefield AJ, Anthony A, Murch SH, Thomson M, Montgomery SM, Davies S, O'Leary JJ, Berelowitz M, Walker-Smith JA. Enterocolitis in children with developmental disorders. *Am J Gastroenterol* 2000;95:2285-2295.
- Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith, JA. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet* 1998;351:637-641.
- Walsh W. Disordered mental metabolism in autistic spectrum. *Defeat Autism Now! Conference*, San Diego, CA, October 2001:94-100.

Address reprint requests to:
James B. Adams, Ph.D.
Arizona State University
P.O. Box 876006
Tempe, AZ 85287-6006

E-mail: jim.adams@asu.edu